Furman, Richard R

Publications

Sort by

Co-Author Network

selected publications

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in ELEVATE-RR. Blood. 2023 Academic Article GET IT
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy. Haematologica. 2023 Academic Article GET IT
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors. Clinical pharmacology in drug development. 2022 Academic Article GET IT
Times cited: 2
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood advances. 2022 Academic Article GET IT
Times cited: 10
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022 Academic Article GET IT
Times cited: 14
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica. 2022 Academic Article GET IT
Times cited: 9
Venetoclax in Previously Treated Waldenström Macroglobulinemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 32
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. Frontiers in oncology. 2021 Academic Article GET IT
Times cited: 4
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. The Lancet. Haematology. 2021 Academic Article GET IT
Times cited: 18
Serologic response to mRNA COVID-19 vaccination in lymphoma patients. American journal of hematology. 2021 Letter GET IT
Times cited: 22
Idelalisib immune-related toxicity is associated with improved treatment response. Leukemia & lymphoma. 2021 Academic Article GET IT
Times cited: 6
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 157
Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. Leukemia. 2021 Academic Article GET IT
Times cited: 8
Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 2021 Academic Article GET IT
Times cited: 30
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood. 2021 Academic Article GET IT
Times cited: 37
Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. Blood. 2021 Academic Article GET IT
Times cited: 15
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia. 2021 Academic Article GET IT
Times cited: 18
Should venetoclax be used with or without anti-CD20 therapy for CLL?. Clinical advances in hematology & oncology : H&O. 2021 Academic Article GET IT
Outcomes in CLL patients with NOTCH1 regulatory pathway mutations. American journal of hematology. 2021 Letter GET IT
Times cited: 3
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leukemia & lymphoma. 2021 Academic Article GET IT
Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial. Haematologica. 2020 Letter GET IT
Times cited: 6
Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020 Academic Article GET IT
Times cited: 197
Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib. Leukemia. 2020 Letter GET IT
Times cited: 7
When Fast Means Faulty. Gastroenterology & hepatology. 2020 Academic Article GET IT
Correction: Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. Leukemia. 2020 Article GET IT
Times cited: 1
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020 Academic Article GET IT
Times cited: 106
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 104
Highlights in B-cell malignancies from the 61st American Society of Hematology Annual Meeting: commentary. Clinical advances in hematology & oncology : H&O. 2020 Academic Article GET IT
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. The Lancet. Haematology. 2019 Academic Article GET IT
Times cited: 97
Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2019 Academic Article GET IT
Times cited: 5
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. Leukemia. 2019 Academic Article GET IT
Times cited: 19
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. Leukemia. 2019 Letter GET IT
Times cited: 21
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood advances. 2019 Academic Article GET IT
Times cited: 76
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leukemia & lymphoma. 2019 Academic Article GET IT
Times cited: 18
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. The Lancet. Haematology. 2019 Academic Article GET IT
Times cited: 45
Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature. 2019 Academic Article GET IT
Times cited: 140
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood advances. 2019 Academic Article GET IT
Times cited: 125
Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nature communications. 2019 Academic Article GET IT
Times cited: 46
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 156
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica. 2019 Academic Article GET IT
Times cited: 24
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019 Academic Article GET IT
Times cited: 57
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019 Academic Article GET IT
Times cited: 161
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. British journal of haematology. 2019 Letter GET IT
Times cited: 8
Current trends in the management of Richter's syndrome. International journal of hematologic oncology. 2019 Review GET IT
A rare colonic manifestation of chronic lymphocytic leukemia. Leukemia & lymphoma. 2018 Letter GET IT
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. British journal of haematology. 2018 Letter GET IT
Times cited: 11
Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leukemia & lymphoma. 2018 Academic Article GET IT
Times cited: 11
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. American journal of hematology. 2018 Academic Article GET IT
Times cited: 48
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018 Academic Article GET IT
Times cited: 69
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. British journal of haematology. 2018 Academic Article GET IT
Times cited: 14
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018 Academic Article GET IT
Times cited: 117
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. British journal of haematology. 2018 Academic Article GET IT
Times cited: 37
Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses. Cancer research. 2018 Academic Article GET IT
Times cited: 28
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA oncology. 2018 Academic Article GET IT
Times cited: 18
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. HemaSphere. 2018 Academic Article GET IT
Times cited: 9
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018 Academic Article GET IT
Times cited: 305
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018 Academic Article GET IT
Times cited: 108
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. The Lancet. Oncology. 2017 Academic Article GET IT
Times cited: 280
Optimal management of the young patient CLL patient. Best practice & research. Clinical haematology. 2017 Review GET IT
Times cited: 2
Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia. 2017 GET IT
Times cited: 39
MicroRNA-155 regulates casein kinase 1 gamma 2: a potential pathogenetic role in chronic lymphocytic leukemia. Blood cancer journal. 2017 Letter GET IT
Times cited: 7
Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor. Haematologica. 2017 Academic Article GET IT
Times cited: 26
Frontline management of chronic lymphocytic leukemia. Clinical advances in hematology & oncology : H&O. 2017 Academic Article GET IT
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2017 Academic Article GET IT
Times cited: 186
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^. Leukemia & lymphoma. 2017 Letter GET IT
Times cited: 6
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. British journal of haematology. 2017 Academic Article GET IT
Times cited: 52
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017 Academic Article GET IT
Times cited: 103
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood. 2017 Academic Article GET IT
Times cited: 100
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. Blood cancer journal. 2017 Letter GET IT
Times cited: 38
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 54
Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22. Leukemia. 2016 Academic Article GET IT
Times cited: 44
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. The Lancet. Haematology. 2016 Academic Article GET IT
Times cited: 30
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma. Blood advances. 2016 Academic Article GET IT
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood advances. 2016 Academic Article GET IT
Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia. Leukemia & lymphoma. 2016 Letter GET IT
Times cited: 2
Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2016 Review GET IT
Times cited: 74
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 258
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clinical epigenetics. 2016 Academic Article GET IT
Times cited: 35
Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016 Academic Article GET IT
Times cited: 191
Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma. Clinical lymphoma, myeloma & leukemia. 2015 Academic Article GET IT
Times cited: 9
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 699
Idelalisib-associated Colitis: Histologic Findings in 14 Patients. The American journal of surgical pathology. 2015 Academic Article GET IT
Times cited: 107
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. The Journal of clinical investigation. 2015 Academic Article GET IT
Times cited: 39
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 182
Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. Cell reports. 2015 Academic Article GET IT
Times cited: 292
Management of adverse events associated with idelalisib treatment: expert panel opinion. Leukemia & lymphoma. 2015 Review GET IT
Times cited: 247
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 16
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 2015 Letter GET IT
Times cited: 19
Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 13
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015 Academic Article GET IT
Times cited: 578
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney international. 2015 Academic Article GET IT
Times cited: 291
Management of chronic lymphocytic leukemia. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2015 Review GET IT
Times cited: 27
Extracorporeal membrane oxygenation as a bridge to chemotherapy in an Orthodox Jewish patient. 2014 GET IT
Times cited: 7
Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab. Leukemia & lymphoma. 2014 Academic Article GET IT
Times cited: 9
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. Journal of hematology & oncology. 2014 Academic Article GET IT
Times cited: 66
To the end of chronic lymphocytic leukemia: what should be the role of allogeneic transplant?. Leukemia & lymphoma. 2014 Letter GET IT
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 1283
Ibrutinib resistance in chronic lymphocytic leukemia. The New England journal of medicine. 2014 Letter GET IT
Times cited: 226
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 902
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014 Academic Article GET IT
Times cited: 222
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014 Academic Article GET IT
Times cited: 189
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 Academic Article GET IT
Times cited: 539
Highlights in B-cell malignancies from the 2013 American Society of Hematology annual meeting and exposition: commentary. Clinical advances in hematology & oncology : H&O. 2014 Academic Article GET IT
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 1408
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014 Academic Article GET IT
Times cited: 231
Clinical roundtable monograph: unmet needs in the treatment of chronic lymphocytic leukemia: integrating a targeted approach. Clinical advances in hematology & oncology : H&O. 2014 Review GET IT
Times cited: 5
Unmet needs in the treatment of chronic lymphocytic leukemia: introduction. Clinical advances in hematology & oncology : H&O. 2014 Academic Article GET IT
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2013 Academic Article GET IT
Times cited: 62
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. The Lancet. Oncology. 2013 Academic Article GET IT
Times cited: 410
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2013 Academic Article GET IT
Times cited: 154
Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results. Clinical lymphoma, myeloma & leukemia. 2013 Academic Article GET IT
Times cited: 12
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013 Academic Article GET IT
Times cited: 588
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 1788
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 1025
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 169
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 924
Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1. Leukemia & lymphoma. 2012 Academic Article GET IT
Times cited: 19
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leukemia & lymphoma. 2012 Academic Article GET IT
Times cited: 23
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 123
Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. Journal of immunology (Baltimore, Md. : 1950). 2012 Academic Article GET IT
Times cited: 65
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clinical lymphoma, myeloma & leukemia. 2012 Academic Article GET IT
Times cited: 44
Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. American journal of hematology. 2012 Letter GET IT
Times cited: 33
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood. 2012 Academic Article GET IT
Times cited: 41
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 2011 Academic Article GET IT
Times cited: 51
CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clinical lymphoma, myeloma & leukemia. 2011 Academic Article GET IT
Times cited: 55
Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis. British journal of haematology. 2011 Letter GET IT
Times cited: 24
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leukemia & lymphoma. 2011 Academic Article GET IT
Times cited: 21
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 491
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 278
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 2010 Academic Article GET IT
Times cited: 46
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 184
New agents in early clinical trials for CLL therapy. Clinical advances in hematology & oncology : H&O. 2010 Academic Article GET IT
Times cited: 2
Cutaneous CD4+ CD56+ hematologic malignancies. 2010 GET IT
Times cited: 14
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010 Academic Article GET IT
Times cited: 52
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clinical lymphoma, myeloma & leukemia. 2010 Academic Article GET IT
Times cited: 45
Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 140
NK/T cell non-Hodgkin lymphoma in a HIV-positive patient. Journal of hematopathology. 2010 Academic Article GET IT
Times cited: 112
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 517
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leukemia & lymphoma. 2010 Academic Article GET IT
Times cited: 96
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Blood. 2010 Academic Article GET IT
Times cited: 38
Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 43
Prognostic markers and stratification of chronic lymphocytic leukemia. Hematology. American Society of Hematology. Education Program. 2010 Academic Article GET IT
Times cited: 33
Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone. 2009 GET IT
Times cited: 79
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 167
Overlap between systemic lupus erythematosus and Kikuchi Fujimoto disease: a clinical pathology conference held by the Department of Rheumatology at Hospital for Special Surgery. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2009 Conference Paper GET IT
Times cited: 203
Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis. 2009 GET IT
Times cited: 4
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009 Academic Article GET IT
Times cited: 785
Outcome of deferred initial therapy in mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 286
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. British journal of haematology. 2008 Academic Article GET IT
Times cited: 43
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood. 2008 Academic Article GET IT
Times cited: 113
New monoclonal antibodies for non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Review GET IT
Times cited: 5
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008 Academic Article GET IT
Times cited: 59
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leukemia & lymphoma. 2008 Academic Article GET IT
Times cited: 15
Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Seminars in hematology. 2008 Review GET IT
Times cited: 16
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 66
Improving outcomes for patients with Burkitt lymphoma and HIV. AIDS patient care and STDs. 2008 Review GET IT
Times cited: 19
Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leukemia & lymphoma. 2008 Academic Article GET IT
Times cited: 35
Persistent and relapsing babesiosis in immunocompromised patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008 Academic Article GET IT
Times cited: 245
Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies. Seminars in oncology. 2007 Review GET IT
Times cited: 23
Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Review GET IT
Times cited: 11
CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia. Journal of translational medicine. 2007 Academic Article GET IT
Times cited: 33
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. 2007 GET IT
Times cited: 21
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. Leukemia & lymphoma. 2007 Academic Article GET IT
Times cited: 11
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006 Academic Article GET IT
Times cited: 167
Systemic antineutrophil cytoplasmic antibody vasculitis in a patient with chronic lymphocytic leukemia: quite a rare diagnosis. 2006 GET IT
Times cited: 11
Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. International journal of cancer. 2006 Review GET IT
Times cited: 52
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer. 2006 Academic Article GET IT
Times cited: 34
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Cancer treatment and research. 2006 Review GET IT
Times cited: 3
New developments in immunotherapy for non-Hodgkin's lymphoma. Current oncology reports. 2005 Review GET IT
Times cited: 10
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 145
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 167
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 205
Epratuzumab in non-Hodgkin's lymphomas. Current treatment options in oncology. 2004 Review GET IT
Times cited: 14
Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia. 2003 Letter GET IT
Times cited: 54
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 237
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2003 Academic Article GET IT
Times cited: 76
Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. Journal of immunology (Baltimore, Md. : 1950). 2000 Academic Article GET IT
Times cited: 240

more ...

less ...

Background

education and training

M.D., Mount Sinai School of Medicine 1993
B.A., Dartmouth College 1989

Contact

full name

Richard R Furman

primary email

rrfurman@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Richard R Furman Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage